Home › Myalgic Encephalomyelitis/Chronic Fatigue Syndrome › NCT07753122

Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Randomized Controlled Trial of Moderate Dose Hydrogen Water as a Treatment for ME/CFS

Who can join

Ages 18 to 65 · All sexes

Inclusion Criteria:

* Patients aged 18-65 of both sexes
* considered physically capable and willing to perform the study tasks
* Meet validated phone-screen eligibility for ME/CFS criteria
* Participant has internet and computer

Exclusion Criteria:

* Cases of fatigue clearly attributable to self-report medical conditions such as untreated hypothyroidism, unstable diabetes mellitus, organ failure, chronic infections, and chronic inflammatory diseases, or AIDS. Kidney disease/renal failure is also an exclusion
* Exclusionary psychiatric disorders include any psychosis, or alcohol/ substance abuse within two years prior to illness onset and any time afterward, and current or past depression with melancholic or psychotic features within 5 years prior to onset of ME/CFS or anytime afterward

  * Pregnancy is an exclusion.

    * Patients with BMI\>35

      \_\_\_\_Patients regularly taking therapeutic magnesium.
    * Patients at significant risk of suicide or in need of urgent psychiatric treatment. As much as possible, appropriate medical and psychiatric referrals to facilities local to subjects will be provided.

About the study

This is a 16-week controlled treatment trial of an over-the -counter supplement, hydrogen water, for individuals with ME/CFS patients. An active treatment condition will be compared to a placebo-control condition. The study will also seek confirmation of heart rate variability (HRV) as a biomarker, that is, as a predictor of improvement vs. non-improvement to be assessed at treatment termination. The HRV biomarker hypothesis is based on a finding that High Frequency HRV (cardio-parasympathetic measure) biologically separated improvers and non-improvers in my previous ME/CFS observational study.

What is being tested

• Placebo condition (dietary supplement)
• Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks. (dietary supplement)

Sponsor: Fred Friedberg · Participants: 80 · Started: Aug 15, 2026

Contact the study team

• Fred Friedberg, PhD · Phone: 16316381931

Official record on ClinicalTrials.gov — NCT07753122

Locations in the U.S.

Conditions

• Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.